Abstract:Abstract Colorectal cancer (CRC) is a heterogeneous malignancy that originates from the colonic and rectal epithelium. It ranks among the most prevalent and deadly cancers globally, representing about 10% of cancer incidence and 9% of cancer mortality in 2018. The oncogenesis and evolution of CRC are driven by the accumulation of genetic and epigenetic alterations that dysregulate key signaling pathways, such as Wnt, RAS, TGF-β, and DNA mismatch repair. However, the molecular mechanisms and vulnerabilities of CRC remain poorly understood, and many patients exhibit poor response or resistance to the current therapies. Therefore, there is an urgent need for novel and effective therapies that can target the specific features and dependencies of different CRC subtypes. To better understand the molecular mechanisms and vulnerabilities of CRC, we established a comprehensive platform based on the CRC model cells derived from human intestinal stem cells (hISCs), patient-derived xenografts (PDXs), and clinical samples, on which we conducted integrative genomic and functional analyses. We employed CRISPR/Cas9 to introduce common CRC mutations, such as APC truncation, KRAS G12D, TP53 and SMAD4 knockouts into hISCs and generated isogenic CRC model cells with different mutational backgrounds. We also developed PDXs from CRC patients and collected biopsy samples from primary and metastatic tumors. We characterized the transcriptomic and genomic profiles of all the samples using RNA-seq and whole-exome sequencing (WES). Then, we conducted high-throughput drug screening (drug HTS) with a collection of standard-of-care drugs and CRISPR/Cas9 dropout screening with a genome-wide library on the CRC model cells. RNA-seq and WES analyses identified distinct molecular signatures and pathways associated with different mutational variants. We validated the presence of driver mutations in the patient-derived cultures, such as APC, KRAS, and TP53, and compared them with the model cells. Our primary cancer cell culture platform was proven suitable for high-throughput identification of new molecular targets through CRISPR/Cas9 dropout screening with a genome-wide library performed on CRC model cells. Additionally, our in-house drug HTS, utilizing a collection of standard-of-care drugs, met industrial standards of QC values such as signal-to-noise ratio, Z-factor, and robustness.. The QC values, such as read depth, library complexity, and alignment rate met the established criteria and we were able to identify essential and tumor suppressor gene sets. Moreover, by utilizing normal hIPCs, we were able to identify among the essential genes those that are critical only for the transformed cells. This innovative platform provides a powerful tool for target discovery and validation in CRC, with potential applicability to other cancer types and personalized medicine approaches. Our findings underscore the importance of using primary material-derived cells in the process of understanding the molecular intricacies of CRC and pave the way for the development of novel, effective therapies. Citation Format: Marcin Duleba, Joanna Szuszkiewicz, Marcin Serocki, Joanna Szklarczyk, Olga Dracz, Anna Ledwon, Michał Combik, Oleksii Bryzghalov, Agata Stachowicz, Michal Mikula, Krzysztof Brzozka, Rafal Dziadziuszko, Tomasz Rzymski, Eliza Zimolag, Andrzej Mazan. A comprehensive platform for unraveling the molecular mechanisms and vulnerabilities of colorectal cancer: A step forward in target discovery [abstract]. In: Proceedings of the AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics; 2023 Oct 11-15; Boston, MA. Philadelphia (PA): AACR; Mol Cancer Ther 2023;22(12 Suppl):Abstract nr A162.

Abstract LB080: iOTarg screening platform reveals novel mechanisms of colorectal cancer evasion from antigen-specific tumor cell killing by T cells

Functional genomic landscape of T-cell mediated cytotoxicity.

Abstract A162: A comprehensive platform for unraveling the molecular mechanisms and vulnerabilities of colorectal cancer: A step forward in target discovery

Abstract 5641: Tumor cell intrinsic factors in colorectal cancer immune evasion

Abstract 6741: Targeting glutamine metabolism potentiates antigen presentation in colorectal cancer

Abstract 2698: TCF-1 is a critical regulator of intraepithelial lymphocytes in colorectal carcinoma

Abstract 1575: The landscape of tumor intrinsic immune regulators revealed by genome-wide CRISPR immune screen integrated with comprehensive clinical data analysis

Abstract 606: Targeting the immune checkpoint PTPN2 with ABBV-CLS-484 inflames the tumor microenvironment and unleashes potent CD8+ T cell immunity

Abstract B52: KRAS-IRF2 axis drives immune suppression and immune therapy resistance in colorectal cancer

Abstract 586: Tumor cell-intrinsic PD-1 activation drives therapeutic resistance in colorectal cancer cells

Abstract 1819: Integrin inhibitor GLPG-0187 promotes T-cell killing of mismatch repair-deficient colorectal cancer cells by suppression of SMAD/TGF-β signaling

Abstract 567: CRISPR/Cas9-mediated CD39 disruption can be combined with TCR editing in T cells to improve the adoptive T cell therapy of colorectal cancer

Abstract 5100: Multimodal real world data reveals immunogenomic drivers of acquired and primary resistance to immune checkpoint blockade

Abstract 2415: Resistance to immune checkpoint inhibitor (ICI) therapy in metastatic melanoma is revealed by deep circulating tumor DNA tracking in concert with tumor immune profiling

Abstract 3964: A cancer survival program against activated T cell attack

Abstract A146: Systematic Discovery of Immune Regulatory Mechanisms in Tumor Cells

Abstract A41: Small molecule inhibition of PTPN2/1 inflames the tumour microenvironment and unleashes potent CD8+ T cell immunity

Abstract PR-04: A TROP2/Claudin program mediates immune exclusion to impede checkpoint blockade in breast cancer

Abstract B039: Elucidating the tumor-driven mechanisms of resistance to immunotherapies in pancreatic cancer through in vivo CRISPR/Cas9 knockout screening

Abstract A050: Enhancing Immune Checkpoint Inhibitor Efficacy by Targeting Neurotrophic Receptor Tyrosine Kinase 1 Signaling in Immune Resistant Non-Small Cell Lung Cancer Patients